Training program in the biology and translational research on Alzheimer's disease and related dementias

摘要 这个T32应用程序寻求对阿尔茨海默病学员的多学科教育的支持， 相关性痴呆（ADRD）神经科学，包括分子和细胞机制的基础生物学 老龄化，表观遗传学和性别，是ADRD培训计划（ADRD-TP）的核心。但该方案 将包括药物发现和开发，临床和转化研究，包括创业， 生物信息学、生物物理学和数据科学。导师/导师团队具有出色的专业知识， 建立这个创新的，跨学科的培训计划，以整合其他不同的中心， UIC和Rush的卓越表现，通过行业合作加以利用。它将提供培训， 神经变性和痴呆症的多学科理解，学员需要重振 寻找治疗方法我们将满足对科学家的迫切需求， 学科导师的专业知识是多样化的;从痴呆症的分子机制，血管生物学，糖尿病 以及炎症、神经元和神经成像技术，用于人类ADRD患者的临床诊断和大规模 数据分析专业知识来自11个部门（解剖学和细胞生物学，神经病学，精神病学，医学， 药理学、麻醉学、生物工程学、计算机科学、药物化学、化学和 运动学）5个学院（医学，药学，工程，文科，应用健康科学），5个临床 和翻译实体（拉什的阿尔茨海默病研究中心， UIC组织库和UIC健康与老龄化研究中心， 临床翻译科学（CCTS）在UIC。我们将培养具有不同背景的ADRD研究人员， 跨学科的技能，包括神经科学家，但也计算生物学家，和感兴趣的工程师 转化型ADRD研究。为了促进跨学科的培训，学员将有一个初级导师 和二级导师;后者利用来自许多学科的同事的技能。我们将建立个人 发展计划（IDPs）为每个学员，并提供多学科课程从ADRD-TP教师，但 还有制药科学家重要的是，学员可以在4个附属临床和医学中心中的1个进行转化研究。 翻译实体将鼓励学员与大型社区NIH支持的 研究（ROS/MAP或NIA的大型合作联盟，AMP-AD，M2 OVE-AD，ADNI，ACTC），并与 我们的行业合作伙伴礼来和艾伯维鼓励学员参加CCTS的讲习班， 芝加哥生物医学联合会（CBC）致力于组学和药物发现， CIM/MATTER创业计划，帮助科学创新的商业化。我们寻求支持 4名研究生。在受训人员的指导下，并利用国内流离失所者，将在整个过程中监测进展情况 培训，由个别论文委员会。总而言之，ADRD-TP将提供严谨、鼓舞人心且 培育环境，以确保培训最高水平的科学家需要解开痴呆症。

ABSTRACT This T32 application seeks support for the multidisciplinary education of trainees in Alzheimer's disease and related dementia (ADRD). Neuroscience, including Basic Biology of molecular and cellular mechanisms of aging, epigenetics and gender, is the core of the ADRD training program (ADRD-TP). However, the program will include Drug Discovery and Development, Clinical and Translational Research including entrepreneurship, and Bioinformatics, Biophysics and Data Science. The mentor/preceptor team has outstanding expertise to establish this innovative, interdisciplinary training program, to integrate otherwise disparate centers of excellence at UIC and Rush, leveraged by industry collaborations. It will provide training in the emerging, multidisciplinary understanding of neurodegeneration and dementia, that trainees need to reinvigorate the search for treatments and cures. We will answer the imperative need for scientists who can synthesize across disciplines. Preceptor expertise is diverse; from molecular mechanisms of dementia, vascular biology, diabetes and inflammation, neuronal and neural imaging to clinical diagnosis of human ADRD patients and large scale data analysis. Expertise is from 11 departments (Anatomy and Cell Biology, Neurology, Psychiatry, Medicine, Pharmacology, Anesthesiology, Bioengineering, Computer science, Medicinal Chemistry, Chemistry, and Kinesiology) 5 colleges (Medicine, Pharmacy, Engineering, Liberal Arts, Applied health sciences), 5 clinical and translational entities (The Alzheimer's Disease Research Center at Rush, the Aging and Memory Clinic at UIC, the UIC tissue repository bank and the Center for Research on Health and Aging at UIC, the Center for Clinical Translation Science (CCTS) at UIC). We will train ADRD researchers with diverse backgrounds and cross-disciplinary skills, including neuroscientists, but also computational biologists, and engineers interested in translational ADRD research. To facilitate interdisciplinary training, trainees will have a primary preceptor and secondary mentor; the latter utilizing skills of associates from many disciplines. We will build individual development plans (IDPs) for each trainee and offer multidisciplinary coursework from ADRD-TP faculty but also pharma scientists. Importantly, trainees can perform translational research at 1 of 4 affiliated clinical and translational entities. Trainees will be encouraged to collaborate with large community-based NIH-supported studies (ROS/MAP or NIA's large-scale collaborative consortia, AMP-AD, M2OVE-AD, ADNI, ACTC), and with our industry partners, Eli Lilly and AbbVie. Trainees are encouraged to participate in workshops of the CCTS, the Chicago Biomedical Consortium (CBC) that is geared towards -omics and drug discovery and the CIM/MATTER entrepreneurial program that aids commercialization of scientific innovation. We seek to support 4 graduate students. With the trainee's mentors and utilizing IDPs, progress will be monitored throughout training, by individual thesis committees. In summary, the ADRD-TP will provide a rigorous, inspiring and nurturing environment to ensure training of the highest level of scientists needed to unravel dementia.